Modeling how methadone works in the body for opioid addiction treatment
Official title: Pharmacokinetic Population Modeling of Methadone in Patients Managed for Opioid Opioid Addiction
Run by University Hospital, Montpellier · NCT05490732 · Data updated 2026-11-12
This study is testing a new way to understand how methadone works in the body to help people with opioid addiction get the right dose and feel better faster.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Montpellier Academic / other |
| Locations | 1 site (Montpellier) |
| Status | Recruiting |
| Started | March 23, 2024 |
| Main results expected | April 1, 2025 |
| Study ends | September 1, 2025 |
| Registry record updated | November 21, 2024 |
| Trial ID | NCT05490732 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults on a stable methadone dosage for at least 7 days who are hospitalized for withdrawal management.
✕Probably not a fit
Patients with weakened veins, those unable to provide informed consent, or individuals under legal protection will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to create a pharmacokinetic model for methadone to better manage opioid addiction. By understanding the variability in how patients metabolize methadone, the study seeks to optimize dosages and reduce withdrawal periods. The approach involves blood sampling to monitor plasma concentrations, allowing for more personalized treatment plans. The goal is to empower patients by providing them with information about their blood levels and improving overall treatment outcomes.
Why it matters
Potential benefit: If successful, this study could lead to more effective and personalized treatment for patients struggling with opioid addiction.
How similar studies have gone: While few population pharmacokinetic models for methadone exist, this approach is relatively novel and has not been extensively tested in the context of opioid addiction management.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major patients on methadone on the same dosage for at least 7 days. * Hospitalization for withdrawal in the addictology department of La Colombière or consultation within the unit for the treatment of drug addiction and dependence (Addictology Department). * 24 hours monitoring is possible and accepted Exclusion Criteria: * Patients that cannot be sampled because of weakened veins * Unable to received information about the study * Exclusion period determined by previous study * Adult protected by law or patient under guardianship * Not affiliated to french social security system * Not able to give written inform consent * Pregnant or breastfeeding woman * Underaged patients (under 18 years old) * Patient under court protection
Where it's running
-
CHU de Montpellier
Montpellier, France Recruiting
Study contacts
- Principal investigator: Yoann Cazaubon, phD,pharmD — University Hospital, Montpellier
- Study coordinator: Yoann Cazaubon, phD,pharmD
- Email: yoann.cazaubon@chu-montpellier.fr
- Phone: +33467336261
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.